Glenmark Pharmaceuticals ltd — Capital/Financing Update 2021

Apr 30, 2021

==> picture [15 x 10] intentionally omitted <==

==> picture [17 x 10] intentionally omitted <==

==> picture [140 x 43] intentionally omitted <==

April 30, 2021

To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Disclosure under Regulation 30 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that Glenmark Pharmaceuticals Limited has entered into an agreement to become a partner in ABCD Technologies LLP (to be renamed as Indo Health Services LLP).

The details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure – A.

Request you to kindly take the same on record.

Thanking you.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Digitally signed by HARISH HARISH VINAYAK KUBER VINAYAK KUBER Date: 2021.04.30 16:49:30 +05'30'

Harish Kuber

Company Secretary & Compliance Officer

Tel: 4018 9999 / 4018 9879 Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

==> picture [15 x 10] intentionally omitted <==

==> picture [17 x 10] intentionally omitted <==

==> picture [140 x 43] intentionally omitted <==

Annexure A

a) Name of the target entity, details in brief such assize, turnover etc.:	i) Name of the Target entity:ABCD Technologies LLP (to be renamed asIndoHealth Services LLP) (hereinafter referred to asTarget entity).ii) Details of Target entity:The Target entity is a recently incorporated limitedliability partnership (“LLP”) and is yet to commencebusiness activities.
b) Whether the acquisition would fall within relatedpartytransaction(s)andwhetherthepromoter/promoter group/group companies haveany interest in the entity being acquired? If yes,nature of interest and details thereof and whetherthe same is done at “arms‐length”;	The transaction does not fall within the purview ofrelated party transaction.None of the promoter/promoter group/groupcompanies have any interest in the entity.
c) Industry to which the entity being acquiredbelongs;	Healthcare Services
d) Objects and effects of acquisition (including butnot limited to, disclosure of reasons for acquisitionof target entity, if its business is outside the mainline of business of the listed entity);	Initiative with an objective to facilitate, enableand promote efficiency and Good DistributionPractices (‘GDP’) including digitizing healthcareinfrastructure in India, inter alia, in support oftheNationalDigitalHealthMissionofGovernment of India (‘Business’).
e) Brief details of any governmental or regulatoryapprovals required for the acquisition;	None
f) Indicative time period for completion of theacquisition;	To be completed on or before 30th April 2021
g)Natureofconsideration‐whethercashconsideration or share swap and details of the same;	Cash infusion as capital contribution
h) Cost of acquisition or the price at which the sharesare acquired;	INR 40 crores
i) Percentage of shareholding / control acquiredand/or number of shares acquired;	6.45% share of profit/ loss in LLP
j) Brief background about the entity acquired interms of products/line of business acquired, date ofincorporation, history of last 3 years turnover,country in which the acquired entity has presenceand any other significant information (in brief);	The Target entity was incorporated on 10thFebruary,2021.The Target entity through its investments inDigiHealthTechnologiesLLP,PharmarackTechnologies Private Limited, Trikaal MediinfotechPrivate Limited, and AIOCD Pharmasofttech AwacsPrivate Limited, aims to achieve the objectives as perclause (d) above_._

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com